BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

Spun out from Lee’s in May and aiming for its first NDA submissions next year, China Ophthalmology Focus is already looking ahead to a Hong Kong IPO and an expansion into other Asian markets with...
BC Extra | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway  Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
BC Extra | Dec 26, 2018
Company News

FDA accepts Acer, Kala NDAs before funding lapse

FDA accepted for review NDAs from Acer Therapeutics Inc. (NASDAQ:ACER) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) before the partial government shutdown blocked the agency from taking on new user fee-based applications. The agency granted Priority Review...
BC Week In Review | Dec 21, 2018
Clinical News

Medix planning Mexican NDA for obesity candidate

Saniona AB (SSE:SANION) said partner Medix Products S.A. de C.V. (Mexico City, Mexico) plans to submit an NDA next half in Mexico for obesity candidate tesofensine (NS2330) after two doses of the compound met the...
BC Week In Review | Mar 16, 2018
Clinical News

Berlin Cures' heart failure candidate well tolerated in Phase I

Berlin Cures Holding AG (Zug, Switzerland) reported data from a Phase I trial in 68 healthy volunteers showing that a single IV infusion of heart failure candidate BC007 was well tolerated and eliminated autoantibodies against...
BC Week In Review | Jan 26, 2018
Clinical News

Saniona reports data from exploratory Phase IIa of Tesomet for Prader-Willi

Saniona AB (SSE:SANION) said data from an exploratory Phase IIa trial evaluating once-daily Tesomet tesofensine/metoprolol in patients with Prader-Willi syndrome showed that plasma concentrations of tesofensine were two to four times higher compared to previous...
BC Week In Review | Jul 7, 2017
Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
BC Extra | Jul 3, 2017
Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
BC Week In Review | Jun 9, 2017
Company News

AstraZeneca grants Recordati commercial rights to Seloken

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Recordati S.p.A. (Milan:REC) European commercial rights to Seloken metoprolol tartrate, Seloken ZOK metoprolol succinate and Logimax metoprolol succinate/felodipine for $300 million up front. AstraZeneca will manufacture and supply the products...
BC Week In Review | May 17, 2017
Clinical News

Saniona begins Phase IIa of Tesomet for Prader-Willi syndrome

Saniona AB (SSE:SANION) began the double-blind, placebo-controlled, Czech and Hungarian Phase IIa TM002 trial to evaluate 0.5 mg/50 mg Tesomet tesofensine/metoprolol once daily for 12 weeks in up to 30 patients with Prader-Willi syndrome. The...
Items per page:
1 - 10 of 88